Innoviva (INVA) Short term Debt (2010 - 2025)

Innoviva posted quarterly Short term Debt of $191.9 million for Q2 2025, little changed on a QoQ basis from $192.2 million in Q1 2025.

Innoviva (INVA) has 10 years of Short term Debt data on file, last reported at $191.9 million in Q2 2025.

For the quarter ending Q2 2025, Short term Debt changed N/A year-over-year to $191.9 million; the trailing twelve-month figure through Jun 2025 stood at $191.9 million (changed N/A YoY), and the FY2024 full-year result was $192.0 million, changed N/A from the prior year.
Short term Debt for Q2 2025 stood at $191.9 million, roughly flat from $192.2 million in the prior quarter.
Across five years, Short term Debt topped out at $192.2 million in Q1 2025 and bottomed at $96.0 million in Q1 2022.
The 3-year median for Short term Debt is $144.0 million (2022), against an average of $144.1 million.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn
7	Evaxion A	62.56 Bn	62.54 Bn	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn
10	Innoviva	1.60 Bn	992.84 Mn	75.83 Mn

Download Data 🔒